Clinical Trials
16 trialsNCT05059444 2025-08-22
ORACLE
Guardant Health, Inc.
Recruiting
NCT05891197 2025-07-01
START
Lyell Immunopharma, Inc.
Terminated
NCT06024109 2025-05-13
BARHYSTER
Aesculap AG
Recruiting
NCT05179824 2025-05-06
Tempus Priority Study: A Pan-tumor Observational Study
Tempus AI
Active not recruiting
NCT04889495 2025-03-19
A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer
Pfizer
Withdrawn
NCT04028479 2024-12-18
ROOT
Taproot Health
Completed
NCT04991051 2024-02-06
HALO
AstraZeneca
Completed
NCT02503436 2023-12-04
C-PATROL
AstraZeneca
Completed
NCT03593681 2021-01-20
nCYT
Boston Scientific Corporation
Completed
NCT03485651 2020-02-06
Natera Ovarian Cancer Detection Assay
Natera, Inc.
Terminated
NCT03471572 2019-12-18
BRCA
AstraZeneca
Completed
NCT02122588 2019-05-21
OVATAR
AstraZeneca
Completed
NCT02478476 2015-06-23
DNA Single Nucleotide Polymorphisms as Predictors of Toxicity
OvaGene Oncology, Inc.
Unknown
NCT00288275 2012-10-05
Correlation of the Chemoresponse Assay With PFS in Patients With Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer
Precision Therapeutics
Terminated
NCT00669422 2012-10-05
ChemoFx® PRO - A Post-Market Data Collection Study
Precision Therapeutics
Terminated
NCT01048814 2011-06-03
Retrospective Case Study to Validate Existing Chemoresponse Marker Test in Ovarian, Peritoneal or Fallopian Cancer Cases
Precision Therapeutics
Completed